Survival rates after resection for localized kidney cancer: 1989 to 2004
Russo P, Jang T, Pettus J, Huang W, Eggener S, O'Brien M, Karellas M, Karanikolas N, Kagiwada M. Survival rates after resection for localized kidney cancer: 1989 to 2004. Cancer 2008, 113: 84-96. PMID: 18470927, PMCID: PMC3985136, DOI: 10.1002/cncr.23520.Peer-Reviewed Original ResearchConceptsProgression-free survivalNumber of nephrectomiesProportion of patientsOverall patient survivalDisease progressionKidney cancerOverall survivalLocal recurrenceDistant metastasisPatient survivalTumor sizeRenal tumorsFive-year progression-free survivalMemorial Sloan-Kettering Cancer CenterMultivariate Cox regression analysisConcomitant lymph node dissectionSelect renal tumorsSurgery-related characteristicsLymph node dissectionYear of surgeryKaplan-Meier methodCox regression analysisCurrent treatment paradigmsSmall renal tumorsTumor size categoriesImmunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBleomycinBone Marrow PurgingCombined Modality TherapyCyclophosphamideCytarabineDisease ProgressionDisease-Free SurvivalDoxorubicinDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesGenes, bcl-2Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansImmunologic FactorsImmunosuppressive AgentsKaplan-Meier EstimateLymphoma, FollicularMaleMiddle AgedMultivariate AnalysisPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionRituximabTime FactorsTransplantation, AutologousTreatment OutcomeVincristineConceptsProgression-free survivalRefractory follicular lymphomaHigh-dose therapyFollicular lymphomaFive-year progression-free survivalPeripheral blood stem cell mobilizationBlood stem cell mobilizationEnd pointHigh-dose AraC.Persistent clinical remissionPrimary end pointSecondary end pointsStem cell harvestStem cell mobilizationBcl-2 rearrangementClinical remissionComplete remissionMolecular remissionPartial responseComplete responseClinical outcomesCell mobilizationMedian numberImmunochemotherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply